Published in Transplantation on August 15, 2011
Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17
Cancer in the transplant recipient. Cold Spring Harb Perspect Med (2013) 1.06
Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev Diabet Stud (2012) 0.99
Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J (2015) 0.97
Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival. Cancer Prev Res (Phila) (2012) 0.96
Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) (2013) 0.85
Peripheral natural killer cell and allo-stimulated T-cell function in kidney transplant recipients associate with cancer risk and immunosuppression-related complications. Kidney Int (2015) 0.85
Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol (2014) 0.85
Skin cancer in organ transplant recipients: more than the immune system. J Am Acad Dermatol (2014) 0.84
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant (2012) 0.83
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. Cancer Prev Res (Phila) (2015) 0.82
Transplantation: mTOR inhibition in kidney transplant recipients. Nat Rev Nephrol (2011) 0.82
Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. Am J Transplant (2013) 0.80
Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience. Springerplus (2015) 0.80
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects. Int J Mol Sci (2016) 0.78
Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma. JAAD Case Rep (2015) 0.78
Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol (2012) 0.78
Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015? World J Transplant (2015) 0.78
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prev Res (Phila) (2016) 0.77
Transplantation: Does switching to a CNI-free regimen reduce cancer risk? Nat Rev Nephrol (2011) 0.75
From rapalogs to anti-aging formula. Oncotarget (2017) 0.75
Skin cancer in immunosuppressed transplant patients: Vigilance matters. World J Hepatol (2015) 0.75
Malignant and noninvasive skin tumours in renal transplant recipients. Dermatol Res Pract (2014) 0.75
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management. World J Gastroenterol (2016) 0.75
The benefits of cancer screening in kidney transplant recipients: a single-center experience. Cancer Med (2015) 0.75
Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med (2015) 0.75
The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation. Eur J Clin Pharmacol (2017) 0.75
Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. Cancers (Basel) (2017) 0.75
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol (2004) 3.40
The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol (2004) 3.30
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol (2013) 2.62
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol (2006) 2.24
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol (2013) 2.20
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.93
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology (2004) 1.79
Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int (2004) 1.79
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76
Retracted Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney Int (2013) 1.75
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol (2012) 1.73
A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis (2007) 1.73
Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62
miR-1915 and miR-1225-5p regulate the expression of CD133, PAX2 and TLR2 in adult renal progenitor cells. PLoS One (2013) 1.52
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int (2012) 1.46
Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant (2004) 1.46
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract (2003) 1.46
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
Influence of the ionic dialysance monitor on Kt measurement in hemodialysis. Am J Kidney Dis (2008) 1.39
Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. J Am Soc Nephrol (2004) 1.37
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression. Transpl Int (2008) 1.37
TLR2 plays a role in the activation of human resident renal stem/progenitor cells. FASEB J (2009) 1.33
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother (2013) 1.21
Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) (2004) 1.21
Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics (2009) 1.18
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol (2004) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother (2011) 1.12
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant (2002) 1.11
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob Agents Chemother (2010) 1.07
Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol (2011) 1.05
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant (2004) 1.05
Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis (2004) 1.05
Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation (2002) 1.04
Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol (2007) 1.03
An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis (2003) 1.02
Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol (2005) 0.99
Immune modulation of human dendritic cells by complement. Eur J Immunol (2007) 0.99
Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol (2004) 0.98
Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int (2008) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int (2010) 0.97
Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant (2005) 0.96
Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis (2004) 0.96
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res (2003) 0.96
Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis. J Am Soc Nephrol (2003) 0.94
Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2. J Biol Chem (2012) 0.93
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med (2011) 0.93
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia (2012) 0.93
CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-kappaB and lyn. J Am Soc Nephrol (2006) 0.92
Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther (2012) 0.91
Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors. Nephrol Dial Transplant (2007) 0.90
The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation (2007) 0.90
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol (2016) 0.90
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. Antimicrob Agents Chemother (2011) 0.88
Microalbuminuria and the metabolic syndrome in non-diabetic black Africans. Diab Vasc Dis Res (2007) 0.88
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob Agents Chemother (2007) 0.88
Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis (2007) 0.88
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant (2005) 0.88
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation (2008) 0.87
The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation (2003) 0.87
Renal transplantation in HIV-infected patients: 2010 update. Kidney Int (2011) 0.86
Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation (2012) 0.86
Skeletal muscle mitochondrial function is preserved in young patients with chronic renal failure. Am J Kidney Dis (2002) 0.86
Terminal ileum intubation in pediatric colonoscopy and diagnostic value of conventional small bowel contrast radiography in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2002) 0.86
Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative. Nephrol Dial Transplant (2011) 0.86
mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant (2011) 0.86
Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol (2004) 0.85
Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation (2004) 0.85
KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J Immunol (2014) 0.85
Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. Transplantation (2009) 0.85
Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem (2003) 0.84
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant (2007) 0.84
Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years. Clin Transplant (2007) 0.84
Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl (2008) 0.84
Renal dysfunction in the setting of HIV/AIDS. Curr HIV/AIDS Rep (2012) 0.84
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation (2004) 0.83
The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int (2011) 0.83
Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol (2004) 0.82
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int (2007) 0.82
Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. Mol Genet Metab (2012) 0.82
Infections and organ transplantation: new challenges for prevention and treatment--a colloquium. Transplantation (2012) 0.82
Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation (2010) 0.82